Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulation

We report the results of a phase II trial in patients with metastatic endocrine tumours from different sites, which aimed to evaluate the anti-tumour activity and toxicity of a cisplatinum and etoposide regimen administered in combination with the somatostatin agonist lanreotide given in slow releas...

Descripción completa

Detalles Bibliográficos
Autores principales: Correale, P, Sciandivasci, A, Intrivici, C, Pascucci, A, Del Vecchio, M T, Marsili, S, Savelli, V, Voltolini, L, Di Bisceglie, M, Guarnieri, A, Gotti, G, Francini, G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360193/
https://www.ncbi.nlm.nih.gov/pubmed/17437022
http://dx.doi.org/10.1038/sj.bjc.6603734

Ejemplares similares

Ejemplares similares